Literature DB >> 11844991

Sickle cell vaso-occlusion: multistep and multicellular paradigm.

Paul S Frenette1.   

Abstract

Sickle cell disease is characterized by recurrent, painful episodes and organ damage resulting from microvascular occlusion. Seminal studies performed 20 years ago revealed increased adherence of sickle erythrocytes to vascular endothelial cells. Subsequent work showed that these interactions were mediated by multiple adhesion pathways, but the relevance of these interactions has not been evaluated in vivo. Clinical data suggest that leukocytes may play a role, because leukocytosis correlates with clinical severity and early death, and administration of myeloid growth factors to patients can precipitate sickle cell crises. In addition, recent experimental data using intravital microscopy indicate that sickle erythrocytes can interact with adherent leukocytes in inflamed postcapillary and collecting venules. A novel multistep model for sickle cell vaso-occlusion is proposed in which endothelial activation is induced by sickle cells or secondary inflammatory stimuli and leads to the recruitment of adherent leukocytes. The resulting adherent leukocytes interact with circulating sickle erythrocytes, and this interaction impedes microvascular blood flow. Finally, irregularly shaped sickle cells become nonspecifically trapped, resulting in vaso-occlusion. The molecular mechanisms and requirements for the heterotypic interactions between erythrocytes and leukocytes are currently unknown and may involve further activation of adherent leukocytes or circulating erythrocytes. This model offers exciting new opportunities for therapeutic intervention and suggests a critical participation of adherent leukocytes in sickle cell vaso-occlusion.

Entities:  

Mesh:

Year:  2002        PMID: 11844991     DOI: 10.1097/00062752-200203000-00003

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  60 in total

Review 1.  The paradox of the neutrophil's role in tissue injury.

Authors:  George B Segel; Marc W Halterman; Marshall A Lichtman
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

2.  Endothelial function in patients with sickle cell anemia during and after sickle cell crises.

Authors:  Arnon Blum; Shay Yeganeh; Aviva Peleg; Fina Vigder; Konstantin Kryuger; Ahmed Khatib; Khalid Khazim; Harold Dauerman
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

Review 3.  Haematology and neurology.

Authors:  Steven Austin; Hannah Cohen; Nick Losseff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

4.  Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Authors:  Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2013-09-19       Impact factor: 22.113

5.  Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease.

Authors:  Enrico M Novelli; Gregory J Kato; Mariana E Hildesheim; Suchitra Barge; Michael P Meyer; Jay Lozier; Andrea Cortese Hassett; Margaret V Ragni; Jeffrey S Isenberg; Mark T Gladwin
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

6.  Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis.

Authors:  E Du; Monica Diez-Silva; Gregory J Kato; Ming Dao; Subra Suresh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

7.  Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.

Authors:  Marilyn J Telen; Ted Wun; Timothy L McCavit; Laura M De Castro; Lakshmanan Krishnamurti; Sophie Lanzkron; Lewis L Hsu; Wally R Smith; Seungshin Rhee; John L Magnani; Helen Thackray
Journal:  Blood       Date:  2015-03-02       Impact factor: 22.113

8.  The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells.

Authors:  M F Whelihan; M J Mooberry; V Zachary; R L Bradford; K I Ataga; K G Mann; N S Key
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

9.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

10.  A preliminary study of psychiatric, familial, and medical characteristics of high-utilizing sickle cell disease patients.

Authors:  Patrick C Carroll; Carlton Haywood; Michelle R Hoot; Sophie Lanzkron
Journal:  Clin J Pain       Date:  2013-04       Impact factor: 3.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.